Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00546871 · ClinicalTrials.gov registry record · Phase 2
Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects
A Phase 2 study, sponsored by Baxalta now part of Shire.
- Completed
- Registry status
- Phase 2
- Development phase
- 49
- Enrollment target
NCT00546871 is a Phase 2 study that has completed, run by Baxalta now part of Shire. The registered enrollment target is 49 participants.
The verdict
NCT00546871, a Phase 2 study, has completed, sponsored by Baxalta now part of Shire.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 49 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the tolerability of IGIV, 10% given subcutaneously and the pharmacokinetics of immunoglobulin G (IgG) following subcutaneous (SC) treatment with IGIV, 10% in subjects with primary immunodeficiency (PID) disorders.
Interventions
- DRUG Immune Globulin Intravenous (Human), 10%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2007-10-03 |
| Est. Completion | 2009-09-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00546871
The ClinicalTrials.gov registry entry for NCT00546871 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baxalta now part of Shire, which has 74 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Immune Globulin Intravenous (Human), 10% is the first listed.
NCT00546871 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00546871 about?
NCT00546871 is a clinical study titled "Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects". The purpose of this study is to evaluate the tolerability of IGIV, 10% given subcutaneously and the pharmacokinetics of immunoglobulin G (IgG) following subcutaneous (SC) treatment with IGIV, 10% in subjects with primary immunodeficiency (PID) disorders.
What is the current status of trial NCT00546871?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 49 participants. The study started on 2007-10-03. Estimated completion is 2009-09-01.
What interventions are being tested in trial NCT00546871?
The interventions under investigation include: Immune Globulin Intravenous (Human), 10% (DRUG).
Who is sponsoring clinical trial NCT00546871?
This trial is sponsored by Baxalta now part of Shire, which has 74 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.